01/22/2026
Perioperative Beta-Blockers: Cardiac Safety First — Analgesic Adjunct Second
Perioperative beta-blockers remain a cornerstone of cardiac risk management, with strong evidence supporting continuation in patients on chronic therapy and avoidance of same-day initiation. When used appropriately, they improve hemodynamic stability and reduce myocardial stress.
Less commonly appreciated is their adjunctive role in multimodal analgesia. Short-acting agents such as esmolol attenuate sympathetic outflow and central sensitization, reducing postoperative pain amplification and opioid requirements — without acting as opioids or sedatives. This effect is mediated through modulation of stress pathways, including downstream influence on substance P–related nociceptive signaling, rather than direct nociceptor blockade.
Importantly:
• Beta-blockers should not be initiated solely for pain control
• Analgesic benefit is adjunctive, not primary
• Careful titration is essential to avoid hypotension, bradycardia, and masked hypovolemia
Within ERAS pathways, beta-blockers can complement regional anesthesia, non-opioid analgesics, and opioid-sparing strategies by improving physiologic stability, decreasing stress responses, and supporting faster recovery with fewer opioid-related adverse effects.
Key takeaway:
Use beta-blockers for the right indication, at the right time, in the right patient — and recognize their role as a supporting player in modern, evidence-based perioperative pain management.
⸻
Selected References
• Kehlet H, Dahl JB. The stress response to surgery: release mechanisms and clinical implications. Anesth Analg. 1993.
• Chia YY et al. Perioperative esmolol infusion reduces postoperative pain and opioid consumption. Anest